Synaptiq Therapeutics launched via acquisition of SYN-001 from Nobias Therapeutics, an MEC-majority-backed company; Nobias retains an equity stake in Synaptiq.
Synaptiq Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing therapies for co-morbid neuropsychiatric disorders
Synaptiq Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing therapies for co-morbid neuropsychiatric disorders. The company is advancing SYN-001 for the treatment of neuropsychiatric symptoms associated with 22q11.2 deletion syndrome (22q11DS).